WO2002083113A3 - Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization - Google Patents

Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization Download PDF

Info

Publication number
WO2002083113A3
WO2002083113A3 PCT/US2002/006252 US0206252W WO02083113A3 WO 2002083113 A3 WO2002083113 A3 WO 2002083113A3 US 0206252 W US0206252 W US 0206252W WO 02083113 A3 WO02083113 A3 WO 02083113A3
Authority
WO
WIPO (PCT)
Prior art keywords
fluticasone
budesonide
steroid
delivery
compositions containing
Prior art date
Application number
PCT/US2002/006252
Other languages
French (fr)
Other versions
WO2002083113A2 (en
Inventor
Partha S Banerjee
Imitiaz A Chaudry
Original Assignee
Dey L P
Partha S Banerjee
Imitiaz A Chaudry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dey L P, Partha S Banerjee, Imitiaz A Chaudry filed Critical Dey L P
Priority to AU2002250199A priority Critical patent/AU2002250199B2/en
Priority to ES02719098.2T priority patent/ES2572973T3/en
Priority to CA2444535A priority patent/CA2444535C/en
Priority to SI200231075A priority patent/SI1385494T1/en
Priority to JP2002580917A priority patent/JP4580145B2/en
Priority to EP02719098.2A priority patent/EP1385494B1/en
Publication of WO2002083113A2 publication Critical patent/WO2002083113A2/en
Publication of WO2002083113A3 publication Critical patent/WO2002083113A3/en
Priority to HK04104465.4A priority patent/HK1061523A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptons of bronchoconstrictive disorders using the compositions provided herein are also provided.
PCT/US2002/006252 2001-04-17 2002-03-01 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization WO2002083113A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2002250199A AU2002250199B2 (en) 2001-04-17 2002-03-01 Formoterol/steroid bronchodilating compositions and methods of use thereof
ES02719098.2T ES2572973T3 (en) 2001-04-17 2002-03-01 Compositions containing formoterol and a steroid for administration to the lungs
CA2444535A CA2444535C (en) 2001-04-17 2002-03-01 Formoterol/steroid bronchodilating compositions and methods of use thereof
SI200231075A SI1385494T1 (en) 2001-04-17 2002-03-01 Compositions containing formoterol and a steroid for delivery into the lungs
JP2002580917A JP4580145B2 (en) 2001-04-17 2002-03-01 Formoterol / steroidal bronchodilator composition and methods of use thereof
EP02719098.2A EP1385494B1 (en) 2001-04-17 2002-03-01 Compositions containing formoterol and a steroid for delivery into the lungs
HK04104465.4A HK1061523A1 (en) 2001-04-17 2004-06-19 Compositions containing formoterol and a steroid for delivery into the lungs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28460701P 2001-04-17 2001-04-17
US60/284,607 2001-04-17
US09/887,496 US20030055026A1 (en) 2001-04-17 2001-06-22 Formoterol/steroid bronchodilating compositions and methods of use thereof
US09/887,496 2001-06-22

Publications (2)

Publication Number Publication Date
WO2002083113A2 WO2002083113A2 (en) 2002-10-24
WO2002083113A3 true WO2002083113A3 (en) 2003-03-20

Family

ID=26962701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/006252 WO2002083113A2 (en) 2001-04-17 2002-03-01 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization

Country Status (10)

Country Link
US (6) US20030055026A1 (en)
EP (1) EP1385494B1 (en)
JP (2) JP4580145B2 (en)
AU (1) AU2002250199B2 (en)
CA (1) CA2444535C (en)
ES (1) ES2572973T3 (en)
HK (1) HK1061523A1 (en)
PT (1) PT1385494T (en)
SI (1) SI1385494T1 (en)
WO (1) WO2002083113A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB0204829D0 (en) * 2002-03-01 2002-04-17 Glaxo Group Ltd A fluid dispensing device
EP2319583A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, budesonide and ipratropium
DK1572217T3 (en) * 2002-12-12 2008-12-15 Nycomed Gmbh Combination drug of R, R-formoterol and ciclesonide
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
US9675637B2 (en) * 2003-07-09 2017-06-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050059643A1 (en) * 2003-08-05 2005-03-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a steroid and a betamimetic
DE10347994A1 (en) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Aqueous aerosol preparation
PE20050941A1 (en) * 2003-12-16 2005-11-08 Nycomed Gmbh AQUEOUS CYCLESOUND SUSPENSIONS FOR MISTING
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2011235943B2 (en) * 2003-12-31 2014-06-26 Cydex Pharmaceuticals, Inc Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
BRPI0418276B8 (en) * 2003-12-31 2021-05-25 Cydex Pharmaceuticals Inc inhalable liquid formulation comprising budesonide
JP2007524698A (en) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト Combination of ciclesonide and glycopyrronium
WO2005097095A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. (r,r)-formoterol in combination with other pharmacological agents
ITRM20040268A1 (en) * 2004-05-31 2004-08-31 Italchimici S P A PHARMACEUTICAL FORMULATION OF A STABLE FORMOTEROL SOLUTION BY INHALATION AND ON ITS PREPARATION.
DE102004029784A1 (en) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1632493A1 (en) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridine derivatives, methods for their preparation and their use as drugs
EP1630163A1 (en) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
DE102004058337A1 (en) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
EP1712220A1 (en) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
EP2397034A1 (en) 2005-07-14 2011-12-21 Lithera, Inc. Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment
EP1915155A1 (en) * 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
US20080319079A1 (en) * 2005-11-23 2008-12-25 Feanny Stephen J Method for Administering Formoterol Using a Nebulizer
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
JP2009520822A (en) * 2005-12-20 2009-05-28 ティカ レーケメデル アーベー Methods and systems for delivering corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197487A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an increased lung deposition
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
WO2007071313A2 (en) * 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
EP2034990A4 (en) * 2006-05-26 2013-03-06 Dey L P Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
GB0612748D0 (en) * 2006-06-27 2006-08-09 Univ College London Hospitals Treatment and/or prevention of inflammatory lung disease
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
GB2443287B (en) * 2006-10-17 2009-05-27 Lipothera Inc Methods, compositions and formulations for the treatment of thyroid eye disease
US20100063016A1 (en) * 2007-02-19 2010-03-11 Cipla Limited Pharmaceutical Combinations
ES2493641T3 (en) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Nasal administration of aqueous corticosteroid solutions
EP2185559A1 (en) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
US8054177B2 (en) * 2007-12-04 2011-11-08 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene using patient monitoring
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
AU2010260513A1 (en) * 2009-06-16 2012-02-02 Wen Tan Use of R-Bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders
JP5717329B2 (en) 2009-10-09 2015-05-13 キヤノン株式会社 Solid-state imaging device and manufacturing method thereof
US20110224176A1 (en) * 2010-01-15 2011-09-15 Lithera, Inc. Lyophilized Cake Formulations
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
CA2814445A1 (en) 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
KR20140025312A (en) 2010-11-24 2014-03-04 리쎄라 인코오포레이티드 Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
EP2749284A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and carmoterol
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
ES2758446T3 (en) 2012-01-23 2020-05-05 Sage Therapeutics Inc Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CN104271112A (en) 2012-04-11 2015-01-07 希普拉有限公司 Pharmaceutical composition comprising arformoterol and fluticasone furoate
JP2016525532A (en) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
MA45276A (en) * 2015-06-18 2018-04-25 Sage Therapeutics Inc NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
CN105748447A (en) * 2016-03-08 2016-07-13 上海现代药物制剂工程研究中心有限公司 Budesonide and formoterol spray inhalation suspension and preparation method thereof
EP3426257A4 (en) 2016-03-08 2019-11-13 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN115989032A (en) 2020-07-31 2023-04-18 化学研究有限公司 Combination therapy for inhalation administration
WO2022217029A1 (en) * 2021-04-09 2022-10-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031964A1 (en) * 1994-05-21 1995-11-30 Glaxo Wellcome Australia Limited Fluticasone propionate formulations
US5674860A (en) * 1991-12-18 1997-10-07 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
WO1999025359A1 (en) * 1997-11-14 1999-05-27 Astrazeneca Ab New composition of matter
WO2000000181A1 (en) * 1998-06-26 2000-01-06 Lds Technologies, Inc. Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO2000023037A1 (en) * 1998-10-17 2000-04-27 Boehringer Ingelheim Pharma Kg Two chamber cartridge for atomizers
WO2000048587A1 (en) * 1999-02-18 2000-08-24 Novartis Ag Combinations of formoterol and fluticasone propionate for asthma
US6150418A (en) * 1998-10-17 2000-11-21 Boehringer Ingelheim Pharma Kg Active substance concentrate with formoterol, suitable for storage
WO2001078737A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and budesonide
WO2001078745A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and fluticasone proprionate

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
DE2366625C2 (en) 1972-02-05 1988-06-09 Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp
SE378109B (en) 1972-05-19 1975-08-18 Bofors Ab
US3994976A (en) * 1974-07-08 1976-11-30 The Dow Chemical Company Substituted phenylthioamidines
PH24267A (en) 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8825892D0 (en) 1988-11-04 1988-12-07 Fisons Plc Pharmaceutical composition
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
SE8903219D0 (en) * 1989-10-02 1989-10-02 Astra Ab PROCESS FOR THE MANUFACTURE OF BUDESONIDE
ATE175801T1 (en) 1990-09-18 1999-01-15 Rodime Plc DIGITAL SERVO CONTROL FOR A DISK DRIVE
US5434304A (en) * 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU663906B2 (en) 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5275212A (en) * 1993-02-24 1994-01-04 Minnesota Mining And Manufacturing Company Aerosol filling method
NZ263084A (en) 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5602110A (en) 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
SE9700134D0 (en) 1997-01-20 1997-01-20 Astra Ab New formulation
US5980949A (en) 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
DE19541689A1 (en) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Medicament contg. ciclesonid and beta2-sympathomimetic
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
PL320856A1 (en) 1994-12-22 1997-11-10 Astra Ab Aerosol drug preparations
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
SE9501384D0 (en) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US6041777A (en) 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
US5733526A (en) 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
SE9603669D0 (en) * 1996-10-08 1996-10-08 Astra Ab New combination
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
SE9604486D0 (en) * 1996-12-05 1996-12-05 Astra Ab Novel formulation
FR2756739B1 (en) * 1996-12-05 2000-04-28 Astra Ab NEW BUDESONIDE FORMULATION
SE9700135D0 (en) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
CA2280099C (en) 1997-02-05 2005-12-27 Jago Pharma Ag Medical aerosol formulations
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
CN100548277C (en) 1997-03-20 2009-10-14 先灵公司 The preparation method of powder agglomerates
WO1998051281A1 (en) * 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
HUP0002533A3 (en) 1997-06-27 2001-03-28 Astra Ab New combination of antiasthma medicaments
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
SE9703407D0 (en) * 1997-09-19 1997-09-19 Astra Ab New use
ATE215820T1 (en) 1997-10-08 2002-04-15 Sepracor Inc DOSAGE FORM FOR ADMINISTRATION OF AEROSOLS
SE9704644D0 (en) 1997-12-12 1997-12-12 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
WO1999036095A1 (en) 1998-01-13 1999-07-22 Astrazeneca Uk Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY
WO1999040939A1 (en) 1998-02-10 1999-08-19 Cangene Corporation Method for the prevention and treatment of a type i hypersensitivity disorder
GB9806462D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
AU759264B2 (en) 1998-05-27 2003-04-10 Euro-Celtique S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the upper respiratory tract and/or the ear
IL140353A0 (en) 1998-06-18 2002-02-10 Boehringer Ingelheim Pharma Pharmaceutical formulations for aerosols with two or more active substances
US5965622A (en) 1998-06-23 1999-10-12 Sepracor Inc. Desformoterol and process for its preparation
CN1158996C (en) 1998-07-24 2004-07-28 杰格研究股份公司 Medicinal aerosol for mulations
PT1102579E (en) 1998-08-04 2003-07-31 Jago Res Ag MEDICINAL AEROSOL FORMULATIONS
DE19835346A1 (en) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Two-part capsule for pharmaceutical preparations for powder inhalers
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
SI1121112T1 (en) * 1998-10-17 2002-10-31 Boehringer Ingelheim Pharma Kg Stable formoterol concentrate
DE19847970A1 (en) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Stable concentrated liquid formulation of inhalable drug, e.g. formoterol or salbutamol, in solution or suspension medium, used after dilution for treatment of respiratory disorders by inhalation
US6235725B1 (en) 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
DK1283036T3 (en) 1998-11-13 2008-03-25 Jagotec Ag Dry powder for inhalation
SE9804003D0 (en) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9804001D0 (en) 1998-11-23 1998-11-23 Astra Ab New process
US6261539B1 (en) 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900834D0 (en) 1999-03-09 1999-03-09 Astra Ab Novel combination
SE9900833D0 (en) 1999-03-09 1999-03-09 Astra Ab Novel combination
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
US6303145B2 (en) 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
US6161535A (en) * 1999-09-27 2000-12-19 Carrier Corporation Method and apparatus for preventing cold spot corrosion in induced-draft gas-fired furnaces
DE19947235A1 (en) 1999-09-30 2001-04-05 Asta Medica Ag New combination of loteprednol and beta¶2¶ adrenoreceptor agonists
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SE9903995D0 (en) 1999-11-03 1999-11-03 Astra Ab New combination
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
JP2003531123A (en) 2000-04-13 2003-10-21 イノバータ・バイオミッド・リミテッド Medicine
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
JP5392880B2 (en) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Stable pharmaceutical solution formulation for pressurized metered dose inhalers
GB0016876D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
WO2002007672A2 (en) 2000-07-19 2002-01-31 Aeropharm Technology, Inc. A medicinal aerosol formulation
SE516555C2 (en) 2000-08-04 2002-01-29 Microdrug Ag electrostatic Powder
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
FI20002177A0 (en) 2000-10-02 2000-10-02 Orion Yhtymae Oyj New combination for asthma therapy
NZ525054A (en) 2000-10-09 2004-11-26 3M Innovative Properties Co Medicinal aerosol formulations
KR100488644B1 (en) * 2000-10-12 2005-05-11 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Novel tiotropium-containing inhalation powder
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
AU2002226986A1 (en) 2000-12-01 2002-06-11 Rheologics, Inc. In vivo delivery methods and compositions
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
SE0004750D0 (en) 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
MXPA03005697A (en) 2000-12-22 2003-10-06 Glaxo Group Ltd Metered dose inhaler for salmeterol xinafoate.
KR20030072614A (en) 2001-01-31 2003-09-15 화이자 프로덕츠 인크. Thiazolyl-, Oxazolyl-, Pyrrolyl-, and Imidazolyl-Acid Amide Derivatives Useful as Inhibitors of PDE4 Isozymes
SK8942003A3 (en) 2001-01-31 2004-10-05 Pfizer Prod Inc Ether derivatives useful as inhibitors
IL156413A0 (en) 2001-01-31 2004-01-04 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
DE60203652T2 (en) 2001-01-31 2005-09-08 Pfizer Products Inc., Groton Nicotinic acid amide derivatives and their mimetics as inhibitors of PDE4 isozymes
DE10104370A1 (en) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Medicinal compositions with fewer side effects
DE10104367A1 (en) 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Medicinal compositions containing betamimetics with fewer side effects
CA2435982C (en) 2001-02-06 2014-05-06 Innovata Biomed Limited Medicaments
ITMI20010428A1 (en) 2001-03-02 2002-09-02 Chemo Breath S A INHALATION COMPOSITIONS BASED ON FORMOTEROL
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
KR100422250B1 (en) * 2001-08-21 2004-03-11 삼성전자주식회사 Portable Computer
EA008165B1 (en) 2001-09-18 2007-04-27 Никомед Данмарк Апс Compositions for treatment of common cold
US6702997B2 (en) * 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (en) * 2001-10-26 2003-08-05 Dey Lp Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease
GB0129395D0 (en) 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20040110845A1 (en) * 2002-12-06 2004-06-10 Ramana Malladi Stabilized albuterol compositions and method of preparation thereof
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674860A (en) * 1991-12-18 1997-10-07 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
WO1995031964A1 (en) * 1994-05-21 1995-11-30 Glaxo Wellcome Australia Limited Fluticasone propionate formulations
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999025359A1 (en) * 1997-11-14 1999-05-27 Astrazeneca Ab New composition of matter
WO2000000181A1 (en) * 1998-06-26 2000-01-06 Lds Technologies, Inc. Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
WO2000023037A1 (en) * 1998-10-17 2000-04-27 Boehringer Ingelheim Pharma Kg Two chamber cartridge for atomizers
US6150418A (en) * 1998-10-17 2000-11-21 Boehringer Ingelheim Pharma Kg Active substance concentrate with formoterol, suitable for storage
WO2000048587A1 (en) * 1999-02-18 2000-08-24 Novartis Ag Combinations of formoterol and fluticasone propionate for asthma
WO2001078737A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and budesonide
WO2001078745A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising formoterol and fluticasone proprionate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMALDONE GERALD C ET AL: "Budesonide inhalation suspension is chemically compatable with other nebulizing formulations.", CHEST, vol. 118, no. 4 Suppl., October 2000 (2000-10-01), Chest 2000;San Francisco, California, USA; October 22-26, 2000, pages 98S, XP009000980, ISSN: 0012-3692 *

Also Published As

Publication number Publication date
PT1385494T (en) 2016-08-17
US20100120734A1 (en) 2010-05-13
US8716348B2 (en) 2014-05-06
EP1385494B1 (en) 2016-05-11
HK1061523A1 (en) 2004-09-24
AU2002250199B2 (en) 2007-07-26
CA2444535C (en) 2010-07-13
US8623851B2 (en) 2014-01-07
US20110166202A1 (en) 2011-07-07
US20140171398A1 (en) 2014-06-19
US20020183293A1 (en) 2002-12-05
US20030055026A1 (en) 2003-03-20
JP2005512944A (en) 2005-05-12
JP4580145B2 (en) 2010-11-10
WO2002083113A2 (en) 2002-10-24
US9597396B2 (en) 2017-03-21
EP1385494A2 (en) 2004-02-04
JP2009235089A (en) 2009-10-15
ES2572973T3 (en) 2016-06-03
SI1385494T1 (en) 2016-09-30
US20100069342A1 (en) 2010-03-18
CA2444535A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
WO2002083113A3 (en) Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
WO2002083079A3 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
WO2005007142A3 (en) Liquid compositions comprising formoterol
HUP0202311A2 (en) Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
MXPA04001875A (en) Pharmaceutical compositions for the treatment of asthma.
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
MY126768A (en) Combinations of formoterol and fluticasone propionate for asthma
WO2000042992A3 (en) Compositions and methods for mucosal delivery
WO2006108556A3 (en) Pharmaceutical aerosol composition
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
BR0008699A (en) Combinations of formoterol and demometasone furoate for asthma
WO2003020219A3 (en) Aerosolized decongestants for the treatment of sinusitis
WO2004019910A3 (en) Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
WO2002047667A3 (en) Novel medicament compositions based on anticholinesterase drugs and on a steroid
EP1089715B8 (en) Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
NO20044496L (en) Dry powder inhalation composition
WO2007101005A3 (en) Compositions and methods for effecting controlled posterior vitreous detachment
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
AU2003225915A1 (en) Formoterol and mometasone aerosol formulations
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
WO2005074983A3 (en) Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
AU6471500A (en) Aqueous nasal formulation
AU3687400A (en) New combination of formoterol and mometasone in a pharmaceutical composition fortreating respiratory disorders, such as asthma, rhinitis and copd
WO2005041864A3 (en) Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
WO2004082590A3 (en) A low dose corticosteroid composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002719098

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002250199

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002580917

Country of ref document: JP

Ref document number: 2444535

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002719098

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002250199

Country of ref document: AU